AR078928A1 - Formulacion oftalmica liquida que comprende lactamas gamma sustituidas, articulo de fabricacion que la comprende y su uso para la preparacion de un medicamento util para tratar la hipertension ocular - Google Patents
Formulacion oftalmica liquida que comprende lactamas gamma sustituidas, articulo de fabricacion que la comprende y su uso para la preparacion de un medicamento util para tratar la hipertension ocularInfo
- Publication number
- AR078928A1 AR078928A1 ARP100104121A ARP100104121A AR078928A1 AR 078928 A1 AR078928 A1 AR 078928A1 AR P100104121 A ARP100104121 A AR P100104121A AR P100104121 A ARP100104121 A AR P100104121A AR 078928 A1 AR078928 A1 AR 078928A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- ophthalmic formulation
- lactamas
- gamma
- medicinal product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulacion oftálmica que comprende al menos un agente terapéuticamente activo a una concentracion de 0,01 a 0,12% (p/v) en un vehículo líquido aceptable desde el punto de vista oftálmico, donde el agente activo posee la formula (1), o una sal farmacéuticamente aceptable del mismo, donde A es -(CH2)6-, cis -CH2CH=CH-(CH2)3-, o -CH2C:::C-(CH2)3-, donde una o dos fracciones de CH2 pueden estar sustituidas con S u O; o A es -(CH2)m-Ar-(CH2)o-, donde Ar es interarileno o heterointerarileno, la suma de m y o es de 1 a 4, y donde una o dos fracciones de CH2 pueden estar sustituidas con S u O; R1 es H o alquilo C1-6 y B es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido. Artículo de fabricacion que comprende un recipiente adaptado para administrar el contenido en forma dosificada, donde el contenido del recipiente comprende la formulacion oftálmica descripta. Uso de la formulacion para la preparacion de un medicamento util para tratar la hipertension ocular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25830809P | 2009-11-05 | 2009-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078928A1 true AR078928A1 (es) | 2011-12-14 |
Family
ID=43416423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104121A AR078928A1 (es) | 2009-11-05 | 2010-11-05 | Formulacion oftalmica liquida que comprende lactamas gamma sustituidas, articulo de fabricacion que la comprende y su uso para la preparacion de un medicamento util para tratar la hipertension ocular |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8952051B2 (es) |
| EP (1) | EP2496214B1 (es) |
| JP (2) | JP2013510172A (es) |
| KR (1) | KR101805939B1 (es) |
| CN (2) | CN102655854A (es) |
| AR (1) | AR078928A1 (es) |
| AU (1) | AU2010315051B2 (es) |
| BR (1) | BR112012010795A2 (es) |
| CA (1) | CA2780268C (es) |
| ES (1) | ES2864735T3 (es) |
| RU (1) | RU2630594C2 (es) |
| TW (1) | TWI586665B (es) |
| WO (1) | WO2011057108A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130029919A1 (en) * | 2011-07-26 | 2013-01-31 | Allergan, Inc. | Two part formulation system for opthalmic delivery |
| BR112014014678A2 (pt) * | 2011-12-16 | 2017-06-13 | Allergan Inc | composições oftálmicas compreendendo copolímeros de enxertia de polivinil caprolactama-acetato de polivinila-polietileno glicol |
| TW201733577A (zh) * | 2016-03-14 | 2017-10-01 | Santen Pharmaceutical Co Ltd | 含有多佐胺、噻嗎洛爾和界面活性劑之醫藥組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6770675B2 (en) * | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
| AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| PT1759702E (pt) * | 2004-05-26 | 2009-04-13 | Arturo Jimenez Bayardo | Método de preparação de uma solução oftálmica de latanoprost e a solução assim produzida |
| US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| US7476747B2 (en) * | 2005-03-10 | 2009-01-13 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| AU2007226957B2 (en) * | 2006-03-20 | 2013-08-15 | Allergan, Inc. | Substituted gamma lactams as prostaglandin EP2 agonists |
| US20100087540A1 (en) | 2008-10-07 | 2010-04-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
-
2010
- 2010-11-04 US US12/939,846 patent/US8952051B2/en active Active
- 2010-11-05 CN CN2010800551803A patent/CN102655854A/zh active Pending
- 2010-11-05 EP EP10779166.7A patent/EP2496214B1/en active Active
- 2010-11-05 TW TW099138230A patent/TWI586665B/zh active
- 2010-11-05 BR BR112012010795A patent/BR112012010795A2/pt not_active IP Right Cessation
- 2010-11-05 CA CA2780268A patent/CA2780268C/en active Active
- 2010-11-05 RU RU2012122614A patent/RU2630594C2/ru active
- 2010-11-05 WO PCT/US2010/055685 patent/WO2011057108A1/en active Application Filing
- 2010-11-05 AR ARP100104121A patent/AR078928A1/es not_active Application Discontinuation
- 2010-11-05 KR KR1020127014537A patent/KR101805939B1/ko active IP Right Grant
- 2010-11-05 JP JP2012538041A patent/JP2013510172A/ja not_active Withdrawn
- 2010-11-05 ES ES10779166T patent/ES2864735T3/es active Active
- 2010-11-05 CN CN201610726830.1A patent/CN106176574A/zh active Pending
- 2010-11-05 AU AU2010315051A patent/AU2010315051B2/en active Active
-
2016
- 2016-07-15 JP JP2016140448A patent/JP6026699B1/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110105581A1 (en) | 2011-05-05 |
| ES2864735T3 (es) | 2021-10-14 |
| TW201130826A (en) | 2011-09-16 |
| BR112012010795A2 (pt) | 2017-08-15 |
| AU2010315051A1 (en) | 2012-05-31 |
| WO2011057108A1 (en) | 2011-05-12 |
| KR20120124059A (ko) | 2012-11-12 |
| EP2496214B1 (en) | 2021-01-06 |
| JP6026699B1 (ja) | 2016-11-16 |
| JP2013510172A (ja) | 2013-03-21 |
| RU2012122614A (ru) | 2013-12-10 |
| CA2780268A1 (en) | 2011-05-12 |
| AU2010315051B2 (en) | 2016-06-02 |
| EP2496214A1 (en) | 2012-09-12 |
| RU2630594C2 (ru) | 2017-09-11 |
| CN102655854A (zh) | 2012-09-05 |
| JP2017014222A (ja) | 2017-01-19 |
| US8952051B2 (en) | 2015-02-10 |
| TWI586665B (zh) | 2017-06-11 |
| CA2780268C (en) | 2018-05-15 |
| KR101805939B1 (ko) | 2017-12-06 |
| CN106176574A (zh) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| IN2014CN02591A (es) | ||
| FI3091029T3 (fi) | Anti-il13-vasta-aineformulaatioita | |
| JP2013520405A5 (es) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| EA201492021A1 (ru) | Антительный состав | |
| WO2012035480A3 (en) | Pharmaceutical compositions of curcumin | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| JP2015007136A5 (es) | ||
| JP2015517556A5 (es) | ||
| IN2014DN08870A (es) | ||
| AR078928A1 (es) | Formulacion oftalmica liquida que comprende lactamas gamma sustituidas, articulo de fabricacion que la comprende y su uso para la preparacion de un medicamento util para tratar la hipertension ocular | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| JP2013518051A5 (es) | ||
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| RU2690490C2 (ru) | Способ стабилизации дибутилгидрокситолуола | |
| MA35050B1 (fr) | Formulation d'otamixaban ayant une stabilité améliorée | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| RU2662067C2 (ru) | Прозрачный водный раствор | |
| CY1122598T1 (el) | Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης | |
| KR20150119082A (ko) | 국소 안구 진통제 | |
| BR112018014354A2 (pt) | processo de fabricação de uma bolsa de infusão estável, pronta para uso para uma formulação sensível à oxidação | |
| RU2014148062A (ru) | Инъекционная фармацевтическая композиция декскетопрофена и трамадола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |